ABSTRACT
We have conjugated the murine monoclonal anti-CD19 antibody B43 to the tyrosine kinase inhibitor genistein to construct an effective immunoconjugate against CD19 antigen positive hematologic malignancies. The scaled-up production and purification of B43 antibody, genistein, and B43-Genistein immunoconjugate permitted the manufacturing of a highly purified clinical-grade B43-Genistein preparation. In clonogenic assays, B43-Genistein elicited selective and potent cytotoxicity against CD19 antigen positive human leukemia cells. To our knowledge, this work represents the first effort of producing a clinical-grade genistein immunoconjugate for treatment of B-lineage leukemia and lymphoma.
Subject(s)
Antibodies, Monoclonal , Antineoplastic Agents , Genistein , Immunoconjugates/chemistry , Antineoplastic Agents/therapeutic use , Genistein/therapeutic use , Humans , Immunoconjugates/therapeutic use , Leukemia/therapy , Lymphoma/therapy , Tumor Cells, Cultured/drug effectsABSTRACT
A most unusual case of tinea versicolor is presented in which the eruption was localized only to the patient's flexural areas. This is an additional case of tinea versicolor appearing in a renal transplant patient undergoing immunosuppressant therapy. The role that immunosuppressive agents may have played in this case is also presented.
